Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...

MariTide (maridebart cafraglutide; previously AMG 133) has emerged as one of Amgen's most promising pipeline projects thanks to its potential to offer once-monthly or even less frequent dosing ...

Investing.com -- Shares of Amgen (NASDAQ: NASDAQ ... MariTide (formerly AMG 133). While the study demonstrated notable weight-loss potential, investor expectations for the drug's efficacy may ...